ALXN Technical Analysis
As of date:9/28/2020
ALXN stock price:113.30
ALXN 50 DMA:107.12
ALXN 200 DMA:104.39
ALXN MACD (200-50):-2.73
ALXN RSI:59.17
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)59.17
Extremely
Oversold

Also see:
ALXN Market Cap History
ALXN Shares Outstanding History
ALXN YTD Return

Quotes delayed 20 minutes
Get Free SEC filing alerts for ALXN:
ALXN SEC Filing Email Alerts ServiceExternal link

Collegium Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for COLL
6 minutes ago


Glu Mobile Breaks Above 200-Day Moving Average - Bullish for GLUU
14 minutes ago


FTF Makes Notable Cross Below Critical Moving Average
16 minutes ago


Bullish Two Hundred Day Moving Average Cross - PRGS
16 minutes ago


Hasbro Breaks Above 200-Day Moving Average - Bullish for HAS
16 minutes ago


CQP Crosses Above Key Moving Average Level
16 minutes ago


Bar Harbor Bankshares Breaks Above 200-Day Moving Average - Bullish for BHB
18 minutes ago


Bullish Two Hundred Day Moving Average Cross - FFA
19 minutes ago


GLP Makes Bullish Cross Above Critical Moving Average
35 minutes ago


Dynex Capital Breaks Below 200-Day Moving Average - Notable for DX
44 minutes ago


COG Makes Notable Cross Below Critical Moving Average
44 minutes ago


VDE Crowded With Sellers
52 minutes ago


Shares of FENY Now Oversold
52 minutes ago


Royal Bank of Canada Breaks Below 200-Day Moving Average - Notable for RY.CA
52 minutes ago


ARX.CA Makes Notable Cross Below Critical Moving Average
1 hour, 3 minutes ago


More Technical Analysis News

ALXN Technical AnalysisALXN RSI
Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, Co. has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.

When researching a stock like Alexion Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from ALXN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for ALXN stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
ALXN DMAALXN MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alexion Pharmaceuticals (ALXN) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

AMGN Technical Analysis
BAX Technical Analysis
BDX Technical Analysis
BIIB Technical Analysis
BMY Technical Analysis
BSX Technical Analysis
CAH Technical Analysis
CELG Technical Analysis
CNC Technical Analysis
COO Technical Analysis
More Healthcare companies »

 

ALXN Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.